Rethinking Adherence: A Proposal for a New Approach to Risk Assessment

Abby R. Rosenberg, MD, MS,^{1,2,3} Catherine Fiona Macpherson, RN, PhD, CPON,^{1,3}
Leah Kroon, MN, RN,¹ and Rebecca Johnson, MD^{1,2,3}

Keywords: adherence, needs assessment, risk assessment, psychosocial care, psychosocial outcomes

THE TERM “ADHERENCE” BROADLY REFERS to the relationship between patient behaviors and the recommendations of the healthcare team.¹ Among adolescent and young adult (AYA) oncology patients between the ages of 15 and 39 years, non-adherence is likely a factor in medical as well as psychosocial outcomes, both of which may be inferior among AYAs as compared to younger or older patients with cancer.^{2,3} However, few studies have analyzed the psychosocial aspects of AYA non-adherence,^{4,5} and current approaches to adherence risk assessment fail to address the unique developmental needs of AYA cancer patients. While new research strives to better define and measure adherence, clinicians may be able to optimize it by considering their patient’s level of maturity and independence, psychosocial challenges, and unmet needs. In this perspective, we propose a new platform for risk assessment that promotes adherence by individualizing interventions and enhancing collaboration between patients and providers. Ultimately, such an approach may improve outcomes in AYA patients with cancer.

AYA “Adherence” in the Literature

Others have reviewed and noted the limitations of the literature describing adherence among AYA oncology patients.^{4,5} Due to significant heterogeneity with respect to both the age of patient groups and definitions of adherence, published rates of non-adherence range from 1% to 100%.^{4,5} Most studies have focused solely on measures of pharmacoadherence (the extent to which a patient follows a prescribed medication regimen),^{6–12} with few investigating health-related behaviors or psychosocial components of adherence among AYAs.^{13–16} Much of the literature is decades old; authors have speculated that there is no incentive to perform new investigations because adherence rates in other AYA populations (e.g., patients with cystic fibrosis,¹⁷ asthma,¹⁸ diabetes,¹⁹ or inflammatory bowel disease²⁰) are comparable to those in cancer patients.⁴ Divergent methodologies further preclude a complete understanding of how to

appropriately identify and intervene with non-adherent patients across the cancer continuum.⁵ Indeed, providers have difficulty recognizing non-adherence or initiating appropriate interventions for non-adherent patients.²¹

These challenges underscore the need for further rigorous research and also raise new questions. For example, there are no clear guidelines regarding what constitutes adequate adherence or how to reduce non-adherence. Meaningful classifications of adherence may require a spectrum that incorporates pharmacoadherence as well as other health behaviors. Additionally, we question the appropriateness of comparing oncology patients to those with other chronic diseases. A diagnosis of cancer not only carries a particular social stigma, but it also requires new life changes, challenges, and perspectives. Whereas many patients with the aforementioned chronic diseases may have had a lifetime to adapt, oncology patients must make dramatic life changes quite quickly. This adaptation is particularly challenging for AYAs, who have variable levels of active participation in the treatment process and who may more poignantly struggle with psychosocial and developmental processes than older or younger patients with cancer.

AYA Developmental Challenges

The inferior outcomes observed in AYA patients have been attributed to a variety of factors, including delays in diagnosis,²² biological factors,²³ and poor accrual of AYA oncology patients in clinical trials.²⁴ These disparities may also be due to the fact that AYA patients have unique developmental needs that go unmet during their cancer experience.²⁵ Adolescence and young adulthood is normally characterized by distinctive challenges, transitions, choices, and milestones related to education, employment, identity, relationships, and family.²⁶ AYA cancer patients may miss or delay the achievement of these milestones while they are undergoing therapy. They may need to withdraw from school or work, become increasingly reliant again on parents or others for help

¹Seattle Children’s Hospital, Seattle, Washington.

²Fred Hutchinson Cancer Research Center, Seattle, Washington.

³University of Washington, Seattle, Washington.

with daily living, and move back into their childhood home. Side effects from cancer therapy may affect body image and sense of self. AYAs may feel removed or absent from life experiences that define career goals, social networks, sexuality, and self-identity. In addition, some may lack the maturity or insight to grasp the short- and long-term consequences of their illness.^{27,28}

Patients vary in their individual responses to challenges to their autonomy during cancer therapy, but the nature of such struggles may color the relationship between AYAs, caregivers, and healthcare providers. AYAs also have distinctive styles of learning and communication that are vastly different from younger or older patients with cancer,^{29,30} necessitating novel approaches to the provision of optimal healthcare delivery.

Collectively, the unique developmental characteristics of the AYA period have the potential to affect adherence negatively, in turn affecting medical and psychosocial outcomes. Indeed, although the relationship between non-adherence and outcomes has never been formally described among AYA cancer patients, non-adherence among younger pediatric oncology patients is known to increase the likelihood of relapse and decrease overall survival.^{31,32}

Improving AYA Adherence

A recent qualitative investigation among AYA oncology patients described a “process of adherence” consisting of three distinct steps.³³ To adhere to a treatment regimen, patients must: (1) recognize the threat to long-term health and well-being posed by their cancer diagnosis, (2) take control of their treatment, and (3) manage it for the duration of therapy

and survivorship. Less adherent behaviors may manifest if any or all of these steps are bypassed. Contextual factors such as sociodemographics, personality, social support, and provider interactions may all contribute to ultimate adherence. Others have suggested specific strategies to promote adherence among AYAs, including individualized anticipatory guidance (e.g., individualized psychologic preparation to help relieve patients’ anxiety of expected stress), ongoing monitoring, and more vigilant management when/if non-adherence is identified.^{4,5}

While these suggestions are helpful, they fail to address the unique developmental needs and challenges of AYA patients previously mentioned.^{27,28} Additionally, the term “adherence” suggests collaboration between patients and providers, but the variable maturity levels and capacities for self-care among AYA patients can dramatically affect their roles as functioning members of their treatment team. Some AYAs with cancer, particularly adolescents, may feel disempowered and have a sense that treatment decisions are being dictated by healthcare providers and/or parents. Young adults attempting to manage their own care may struggle with complex treatment regimens that include frequent clinic visits and multiple medications, offering little flexibility for patient decision making. Patients may be deliberately non-adherent in an effort to exercise control and create a sense of independence.

We propose a flexible algorithm to inform clinicians of the risk of non-adherence and guide corresponding clinical care (Fig. 1). This algorithm is based on clinical observations, an understanding of AYA development, and questions raised in the existing literature. We include consideration of the patient’s maturity and independence and his or her psychosocial

FIG. 1. Proposed algorithm for flexible risk assessment of adherence among AYA oncology patients. *Suggested additional supportive care services depend on identified needs and may include referrals to social work, palliative care, child life, psychology, psychiatry, or chaplaincy. AYA, adolescent and young adult.

TABLE 1. EXAMPLES OF CONTEXTUAL ISSUES THAT CONTRIBUTE TO AYA CANCER PATIENT NON-ADHERENCE AND REFERRAL SERVICES TO MITIGATE THESE ISSUES

Context	Examples	Referral services to assist with meeting patient needs
Emotional	<ul style="list-style-type: none"> Psychological distress <ul style="list-style-type: none"> Depression, anxiety Difficulties with coping/adjustment 	AYA psychologist Social worker Chaplain Peer support groups
Social	<ul style="list-style-type: none"> Social isolation Lack of caregiver support Developmentally appropriate social milestones unmet <ul style="list-style-type: none"> Drivers' license, school graduation, independent employment, marriage 	Child life or AYA life specialist, social workers Peer support groups Organizations/AYA networking groups (i.e., Gilda's Club, Stupid Cancer, Inerman's Angels) Camps with AYA programming
Financial	<ul style="list-style-type: none"> General financial stressors <ul style="list-style-type: none"> Inability to work and loss of income Expenses related to medical care Employment concerns <ul style="list-style-type: none"> Cancer-related unemployment Disability rights Employer accommodations Lack of insurance or underinsured <ul style="list-style-type: none"> Access to comprehensive care for treatment of cancer Access to affordable medications 	Social worker Hospital-based financial counselors National or community-based organizations that provide financial support (i.e., Rise Above It), legal assistance/advice, employment assistance/advocacy (i.e., LiveStrong Navigation Services, Cancer and Careers) Social workers National or community-based organizations that provide legal assistance/advice (i.e., Cancer Legal Resource Center, LiveStrong Navigation Services), or assistance with procuring lower-cost medications (i.e., Needy Meds)

AYA, adolescent and young adult.

challenges and unmet needs. This algorithm has yet to be tested in clinical research; rather, it provides a possible platform for clinicians to support patient adherence better and, in turn, improve patient outcomes. To our knowledge, no formal assessment tool of this type currently exists.

To assess the risk for non-adherence in AYAs accurately, providers must first form developmentally appropriate expectations regarding a patient's intellectual maturity and independence. For example, it might be unreasonable for providers to expect a 15-year-old patient to assume full responsibility for his cancer treatment; even older patients may lack insight into how their cancer diagnosis and treatment should affect their day-to-day choices. Providers should also consider patients' prior history of adherence as an indication of their level of independence. Second, to help patients effectively meet the demands of their treatment, the healthcare team should formally assess needs and challenges, and then direct patients to available resources (Table 1). Healthcare providers can promote adherence by recognizing and treating emotional stressors (e.g., distress or anxiety), by encouraging or identifying social support networks, by enabling important milestones to be met, and by providing resources for patients with financial hardships (e.g., medical insurance, job security, or transportation costs). Optimizing supportive care strategies to minimize treatment-related symptoms may maximize a patient's overall coping ability and potentially improve adherence. Continued unmet needs suggest greater risk; patients may not be able to prioritize their treatment over those needs. Using the approach described here, few AYA patients would be considered as "low-risk" for non-adherence. The majority of AYAs would benefit from additional clinical monitoring, communication, ongoing needs assessments, and supportive care services to enhance the therapeutic alliance and ultimately achieve better outcomes.

Summary

Although adherence is a topic of considerable interest in AYA oncology, current approaches to assessment and management of adherence fail to address the unique developmental needs of AYA patients. We propose that innovative and flexible assessments of AYAs' risk for non-adherence should include consideration of patient maturity and insight, as well as psychosocial needs. Further refinement of such tools should be a priority for health services researchers specializing in AYA oncology. Careful assessment of AYAs' risk for non-adherence will enable constructive collaborations between patients and providers, promote the use of innovative and individualized interventions to support AYA adherence, and ultimately contribute to superior outcomes among AYAs with cancer.

Acknowledgment

ARR was supported by the Ruth L. Kirschstein National Research Service Award T32CA009351.

Author Disclosure Statement

No competing financial interests exist.

References

- Chisholm-Burns MA, Spivey CA. Pharmacoadherence: a new term for a significant problem. *Am J Health Syst Pharm.* 2008;65(7):661-7.
- Bleyer A. Young adult oncology: the patients and their survival challenges. *CA Cancer J Clin.* 2007;57(4):242-55.
- Kazak AE, Derosa BW, Schwartz LA, et al. Psychological outcomes and health beliefs in adolescent and young adult

- survivors of childhood cancer and controls. *J Clin Oncol*. 2010;28(12):2002–7.
4. Butow P, Palmer S, Pai A, et al. Review of adherence-related issues in adolescents and young adults with cancer. *J Clin Oncol*. 2010;28(32):4800–9.
 5. Kondryn HJ, Edmondson CL, Hill J, Eden TO. Treatment non-adherence in teenage and young adult patients with cancer. *Lancet Oncol*. 2011;12(1):100–8.
 6. Smith SD, Rosen D, Trueworthy RC, Lowman JT. A reliable method for evaluating drug compliance in children with cancer. *Cancer*. 1979;43(1):169–73.
 7. Lansky SB, Smith SD, Cairns NU, Cairns GF, Jr. Psychological correlates of compliance. *Am J Pediatr Hematol Oncol*. 1983;5(1):87–92.
 8. Cohen DG. Treatment refusal in adolescents. *Semin Oncol Nurs*. 1986;2(2):112–6.
 9. Tebbi CK, Cummings KM, Zevon MA, et al. Compliance of pediatric and adolescent cancer patients. *Cancer*. 1986;58(5):1179–84.
 10. Festa RS, Tamaroff MH, Chasalow F, Lanzkowsky P. Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment. *J Pediatr*. 1992;120(5):807–11.
 11. Lancaster D, Lennard L, Lilleyman JS. Profile of non-compliance in lymphoblastic leukaemia. *Arch Dis Child*. 1997;76(4):365–6.
 12. Mitchell AE, Scarcella DL, Rigutto GL, et al. Cancer in adolescents and young adults: treatment and outcome in Victoria. *Med J Aust*. 2004;180(2):59–62.
 13. Dolgin MJ, Katz ER, Doctors SR, Siegel SE. Caregivers' perceptions of medical compliance in adolescents with cancer. *J Adolesc Health Care*. 1986;7(1):22–7.
 14. Jamison RN, Lewis S, Burish TG. Cooperation with treatment in adolescent cancer patients. *J Adolesc Health Care*. 1986;7(3):162–7.
 15. Phipps S, DeCuir-Whalley S. Adherence issues in pediatric bone marrow transplantation. *J Pediatr Psychol*. 1990;15(4):459–75.
 16. Kondryn HJ, Edmondson CL, Hill JW, Eden TO. Treatment non-adherence in teenage and young adult cancer patients: a preliminary study of patient perceptions. *Psychooncology*. 2009;18(12):1327–32.
 17. DeLambo KE, Ievers-Landis CE, Drotar D, Quittner AL. Association of observed family relationship quality and problem-solving skills with treatment adherence in older children and adolescents with cystic fibrosis. *J Pediatr Psychol*. 2004;29(5):343–53.
 18. Dahl J, Gustafsson D, Melin L. Effects of a behavioral treatment program on children with asthma. *J Asthma*. 1990;27(1):41–6.
 19. Ellis DA, Frey MA, Naar-King S, et al. Use of multisystemic therapy to improve regimen adherence among adolescents with type 1 diabetes in chronic poor metabolic control: a randomized controlled trial. *Diabetes Care*. 2005;28(7):1604–10.
 20. Hommel KA, Davis CM, Baldassano RN. Medication adherence and quality of life in pediatric inflammatory bowel disease. *J Pediatr Psychol*. 2008;33(8):867–74.
 21. Windebank KP, Spinetta JJ. Do as I say or die: compliance in adolescents with cancer. *Pediatr Blood Cancer*. 2008;50(5 Suppl):1099–100.
 22. Bleyer A. The adolescent and young adult gap in cancer care and outcome. *Curr Probl Pediatr Adolesc Health Care*. 2005;35(5):182–217.
 23. Bleyer A, Barr R, Hayes-Lattin B, et al. The distinctive biology of cancer in adolescents and young adults. *Nat Rev Cancer*. 2008;8(4):288–98.
 24. Fern L, Davies S, Eden T, et al. Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group. *Br J Cancer*. 2008;99(12):1967–74.
 25. Zeltzer LK, Recklitis C, Buchbinder D, et al. Psychological status in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. *J Clin Oncol*. 2009;27(14):2396–404.
 26. Needleman RD. Overview and assessment of variability. In: Behrman RE, Kliegman RM, Jenson HB (Eds). *Nelson textbook of pediatrics* (17th Ed). Philadelphia, PA: Elsevier Science; 2003; pp. 23–7.
 27. Eiser C, Penn A, Katz E, Barr R. Psychosocial issues and quality of life. *Semin Oncol*. 2009;36(3):275–80.
 28. Zebrack BJ. Psychological, social, and behavioral issues for young adults with cancer. *Cancer*. 2011;117(10 Suppl):2289–94.
 29. Albritton K, Bleyer WA. The management of cancer in the older adolescent. *Eur J Cancer*. 2003;39(18):2584–99.
 30. Evan EE, Zeltzer LK. Psychosocial dimensions of cancer in adolescents and young adults. *Cancer*. 2006;107(7 Suppl):1663–71.
 31. Lilleyman JS, Lennard L. Non-compliance with oral chemotherapy in childhood leukaemia. *BMJ*. 1996;313(7067):1219–20.
 32. Peeters M, Koren G, Jakubovicz D, Zipursky A. Physician compliance and relapse rates of acute lymphoblastic leukemia in children. *Clin Pharmacol Ther*. 1988;43(3):228–32.
 33. Landier W, Hughes CB, Calvillo ER, et al. A grounded theory of the process of adherence to oral chemotherapy in Hispanic and caucasian children and adolescents with acute lymphoblastic leukemia. *J Pediatr Oncol Nurs*. 2011;28(4):203–23.

Address correspondence to:
 Abby R. Rosenberg, MD, MS
 Seattle Children's Hospital
 Division of Hematology/Oncology
 M/S B-6553; PO Box 5371
 Seattle, WA 98105

Email: abby.rosenberg@seattlechildrens.org